Area of research
Oncology · Surgery
Research interest
Research focused on Immune system and Bladder cancer, with related work in CD8, TIGIT, Clear cell renal cell carcinoma. Notable publications include 'Intratumoral TIGIT + CD8 + T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer', 'Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients', and 'Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer'.
Immunosuppressive tumor-associated macrophages expressing interlukin-10 conferred poor prognosis and therapeutic vulnerability in patients with muscle-invasive bladder cancer
Infiltration and Polarization of Tumor-associated Macrophages Predict Prognosis and Therapeutic Benefit in Muscle-Invasive Bladder Cancer
Single-cell transcriptomic identified HIF1A as a target for attenuating acute rejection after heart transplantation
Intratumoral TIGIT<sup>+</sup> CD8<sup>+</sup> T-cell infiltration determines poor prognosis and immune evasion in patients with muscle-invasive bladder cancer
Tumor-infiltrating CD39+CD8+ T cells determine poor prognosis and immune evasion in clear cell renal cell carcinoma patients
Identification and validation of dichotomous immune subtypes based on intratumoral immune cells infiltration in clear cell renal cell carcinoma patients
Stromal LAG-3<sup>+</sup> cells infiltration defines poor prognosis subtype muscle-invasive bladder cancer with immunoevasive contexture
CCR8 blockade primes anti-tumor immunity through intratumoral regulatory T cells destabilization in muscle-invasive bladder cancer
Tumor-infiltrating TNFRSF9 <sup>+</sup> CD8 <sup>+</sup> T cells define different subsets of clear cell renal cell carcinoma with prognosis and immunotherapeutic response
CD19+ tumor-infiltrating B-cells prime CD4+ T-cell immunity and predict platinum-based chemotherapy efficacy in muscle-invasive bladder cancer
High expression of Solute Carrier Family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma